There are 410 resources available
Is there a role for repeat biopsies when patients progress on targeted therapy? On Immunotherapy?
Presenter: Valsamo Anagnostou
Session: Resistance after IO and targeted therapies: Patterns of emergence and management
Resources:
Slides
Webcast
The quest for optimal integration of biomarker testing by tissue NGS in the care pathway: Analytics, availability and reporting of actionable vs non-actionable aberrations
Presenter: Javier Hernandez-Losa
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Second vote and conclusions
Presenter: Corinne Faivre-Finn
Session: Stereotactic RT vs surgery in early stage NCSLC
Resources:
Slides
Webcast
Q&A
Presenter: Solange Peters
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Optimal use of local therapy in patients with resistance to targeted therapies or immunotherapy
Presenter: Suresh Senan
Session: Resistance after IO and targeted therapies: Patterns of emergence and management
Resources:
Slides
Webcast
Q&A
Presenter: Zofia Piotrowska
Session: Resistance after IO and targeted therapies: Patterns of emergence and management
Resources:
Webcast
The quest for optimal positioning of liquid biopsies in the workup of patients with NSCLC: When, for what and how often
Presenter: Umberto Malapelle
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Highlighting the value of Molecular Tumour Boards: Presentation of two patient cases with oncogene-addicted NSCLC, summary of clinical evidence and insights in molecular profiling/interpretation
Presenter: Simon Ekman
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Concluding remarks
Presenter: Benjamin Besse
Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage
Resources:
Webcast
Introduction and first vote
Presenter: Lizza Hendriks
Session: Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?
Resources:
Slides
Webcast